Sangamo's HIV-AIDS program is at the top of the chart (farthest along). Two ongoing Phase II trials (SB-728-T 1101 and 1401). Basically, these programs are fine tuning treatment protocols by incorporating Cytoxan preconditioning, and mRNA delivery, which will allow multiple dosing. UPenn is conducting a similar study, but haven't heard anything about that lately. The other Sangamo clinical trial, which deals with stem cells (SB-728-HSPC) is just getting started and is being conducted at City of Hope, which is also where the Hemo B trial will be taking place. Sangamo is seeking to partner the HIV-AIDS program to take it thru Phase III and commercialization. IF they can't find a big pharma or big biotech to partner with, the program may be dropped. This is the big "IF". The results so far have been quite positive (reduced viral load, both circulating and in the reservoirs). Several patients have remained off ART for extended time periods and viral loads remain very low or non-detectable. A "functional cure" is still very much the goal.